<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082753</url>
  </required_header>
  <id_info>
    <org_study_id>988-2020</org_study_id>
    <nct_id>NCT05082753</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study to Compare Two Tablets of Ivermectin Tablets (3 mg Ivermectin) Versus Two Tablets of Stromectol ® Tablets (3 mg Ivermectin), in Healthy Subjects Under Fasting Conditions</brief_title>
  <official_title>Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Two Tablets of Ivermectin Tablets (3 mg Ivermectin) Versus Two Tablets of Stromectol ® Tablets (3 mg Ivermectin), in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmactive Ilac Sanayi ve Tic A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmactive Ilac Sanayi ve Tic A.S.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence&#xD;
      study to compare two tablets of Ivermectin tablets (3 mg Ivermectin) versus two tablets of&#xD;
      Stromectol ® tablets (3 mg Ivermectin), in healthy subjects under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Actual">December 21, 2020</completion_date>
  <primary_completion_date type="Actual">December 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>72 hours</time_frame>
    <description>Statistical analysis of primary endpoints will include descriptive statistics, Analysis of Variance (ANOVA), and Confidence Interval (CI). The average bioequivalence of the products is concluded if the two-sided 90 % CI for the test to reference ratio of the population means is within 80.00 - 125.00 % for each of the Ln-transformed data for Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72 (due to Ivermectin long half-life)</measure>
    <time_frame>72 hours</time_frame>
    <description>Statistical analysis of primary endpoints will include descriptive statistics, Analysis of Variance (ANOVA), and Confidence Interval (CI). The average bioequivalence of the products is concluded if the two-sided 90 % CI for the test to reference ratio of the population means is within 80.00 - 125.00 % for each of the Ln-transformed data for AUC0-72</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>72 hours</time_frame>
    <description>The descriptive statistics including Maximum, Minimum and Median values will be measured for Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (safety and tolerability)</measure>
    <time_frame>at pre-dosing; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 and 72 hours post-dosing, ±45 minutes of scheduled time</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of blood pressure &gt; 90/60 and &lt;140/90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse (safety and tolerability)</measure>
    <time_frame>at pre-dosing; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 and 72 hours post-dosing, ±45 minutes of scheduled time</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of Pulse 60-100 b/m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature (safety and tolerability)</measure>
    <time_frame>at pre-dosing; 4, 12, 24, 48 and 72 hours post-dosing, ±45 minutes of scheduled time</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of temperature 36.5-37.5 ºC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Anthelmintic Agent</condition>
  <arm_group>
    <arm_group_label>Ivermectin tablets (3 mg Ivermectin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stromectol ® tablets (3 mg Ivermectin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin tablets (3 mg Ivermectin)</intervention_name>
    <description>Two Ivermectin tablets were administered orally.</description>
    <arm_group_label>Ivermectin tablets (3 mg Ivermectin)</arm_group_label>
    <arm_group_label>Stromectol ® tablets (3 mg Ivermectin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stromectol ® tablets</intervention_name>
    <description>Two Ivermectin tablets were administered orally.</description>
    <arm_group_label>Ivermectin tablets (3 mg Ivermectin)</arm_group_label>
    <arm_group_label>Stromectol ® tablets (3 mg Ivermectin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is aged between eighteen to fifty years (18 - 50), both inclusive.&#xD;
&#xD;
          -  The subject is within the limits for his height &amp; weight as defined by the body mass&#xD;
             index range (18.5 - 30.0 Kg/m2).&#xD;
&#xD;
          -  The subject is willing to undergo the necessary pre- &amp; post- medical examinations set&#xD;
             by this study.&#xD;
&#xD;
          -  The results of medical history, physical examination, vital signs &amp; conducted medical&#xD;
             laboratory tests are normal as determined by the clinical investigator.&#xD;
&#xD;
          -  The subject tested negative for hepatitis (B &amp; C) viruses and human immunodeficiency&#xD;
             virus (HIV).&#xD;
&#xD;
          -  There is no evidence of psychiatric disorder, antagonistic personality, and poor&#xD;
             motivation, emotional or intellectual problems likely to limit the validity of consent&#xD;
             to participate in the study or limit the ability to comply with protocol requirements.&#xD;
&#xD;
          -  The subject is able to understand and willing to sign the informed consent form.&#xD;
&#xD;
          -  For female subjects: negative pregnancy test and the woman is using two reliable&#xD;
             contraception methods&#xD;
&#xD;
          -  The subject has normal cardiovascular system &amp; ECG recording.&#xD;
&#xD;
          -  The subject kidney functions test and liver enzymes (AST &amp; ALT enzymes) are within&#xD;
             normal range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is a heavy smoker (more than 10 cigarettes per day).&#xD;
&#xD;
          -  The subject has suffered an acute illness one week before dosing.&#xD;
&#xD;
          -  The subject has a history of or concurrent abuse of alcohol.&#xD;
&#xD;
          -  The subject has a history of or concurrent abuse of illicit drugs.&#xD;
&#xD;
          -  The subject has a history of hypersensitivity and/or contraindications to the study&#xD;
             drug and any related compounds.&#xD;
&#xD;
          -  The subject has been hospitalized within three months before the study or during the&#xD;
             study.&#xD;
&#xD;
          -  The subject is vegetarian.&#xD;
&#xD;
          -  The subject has consumed caffeine or xanthine containing beverages or foodstuffs&#xD;
             within two days before dosing and until 72 hours after dosing in all study periods.&#xD;
&#xD;
          -  The subject has taken a prescription medication within two weeks or even an over the&#xD;
             counter product (OTC) within one week before dosing in each study period and any time&#xD;
             during the study, unless otherwise judged acceptable by the clinical investigator.&#xD;
&#xD;
          -  The subject has taken grapefruit containing beverages or foodstuffs within seven (7)&#xD;
             days before first dosing and any time during the study.&#xD;
&#xD;
          -  The subject has been participating in any clinical study (e.g. pharmacokinetics,&#xD;
             bioavailability and bioequivalence studies) within the last 80 days prior to the&#xD;
             present study.&#xD;
&#xD;
          -  The subject has donated blood within 80 days before first dosing.&#xD;
&#xD;
          -  The subject has a history or presence of cardiovascular, pulmonary, renal, hepatic,&#xD;
             gastrointestinal, hematological, endocrinal, immunological, dermatological,&#xD;
             neurological, musculoskeletal or psychiatric diseases.&#xD;
&#xD;
          -  The subject has consumed drugs or foodstuffs that may affect pharmacological or&#xD;
             pharmacokinetic properties (for example: barbiturates (such as phenobarbital,&#xD;
             butalbital), benzodiazepines (such as clonazepam, lorazepam), sodium oxybate (GHB),&#xD;
             valproic acid, warfarin.) two weeks before dosing, during the study and two weeks&#xD;
             after dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ACDIMA Biocenter</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

